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Background
Risk factors of cardiovascular diseases after kidney transplantation are eliminated by restoration of renal functions; however, new risks such as impaired glucose tolerance, diabetes mellitus, artery hypertension, and fat metabolism disorders appear simultaneously. New-onset diabetes mellitus after transplantation (NODAT) is a severe and frequent complication of solid organ transplantations. Incidence of this phenomenon ranges from 4% to 25% according to the transplanted organ, the length of monitoring, and the applied immunosuppressive protocol. Incidence of NODAT 12 months after transplantation is shown in Table 1 [1] [2] [3] [4] .Glucose regulation disorder in patients after kidney transplantation leads to 2-3 times higher cardiovascular morbidity and mortality compared with non-diabetic patients, and the quality of life is lowered. The risk of cardiovascular diseases (CVD) development in patients with NODAT is also increased by hyperlipidemia, artery hypertension, and smoking. NODAT is also related to other complications such as graft rejection, relapsing infections, and worsened long-term graft function [5] . Besides the well-known long-term complications of diabetes mellitus in patients after kidney transplantation with NODAT (as well with fasting hyperglycemia and impaired glucose tolerance), we can observe graft hyperfiltration, which adversely affects function and survival of the transplanted kidney. This population of patients has faster onset of vascular complications and increased mortality in comparison with "normoglycemic" patients [5] [6] [7] . There is increased cardiovascular mortality and morbidity, higher risk of serious infectional and neuropsychic complications, and higher risk of rejection and worsened graft survival in patients after liver transplantation with NODAT [8, 9] . There was a higher incidence of cytomegalovirus (CMV) infection and acute rejection among patients with NODAT after lung transplantation, but increased mortality in comparison with patients without NODAT was not recorded in this case [10] . Waist circumference is the most important diagnostic criterion for metabolic syndrome. Waist circumference measurement in clinical practice is a simple measurable factor for risk control. At present, it is preferred to use values of waist circumference greater than 102 cm in men and 88 cm in women as the most convenient method for diagnosing obesity (according to Adult Treatment Panel III), suggesting that the criteria of the International Diabetic Federation (IDF) have clearly recommended different criteria for individual world populations, with a proposal for marginal waist circumference of 94 cm in men and 80 cm in women for the European population as the basic required criterion (Table 2) [11]. Visceral obesity is a key factor for diabetes mellitus type 2 and metabolic syndrome development and is an independent risk factor for cardiovascular diseases. In the original concept of metabolic syndrome, increased adiposity was predominantly considered to be a secondary consequence of the adipogenic effect of chronic hyperinsulinemia, but currently it is being emphasized that increased adiposity is, together with insulin resistance and hyperinsulinemia, the primary cause of diabetes mellitus and metabolic syndrome. We assume that, as in case of patients with diabetes mellitus type 2, waist circumference will also influence development of NODAT in the population of patients after kidney transplantation [12] .
Material and Methods
We retrospectively evaluated selected risk factors for NODAT in a series of 167 patients (Europids) after primary kidney transplantation from a dead donor (in the years [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] in the Transplant Center Martin. We examined waist circumference, body mass index (BMI), and weight gain from transplantation in the 12 th month after transplantation. We further examined the average level of triglycerides (mmol/l) and total cholesterol (mmol/l) throughout 12 months after kidney transplantation and lipid-lowering therapy. We recorded the type of immunosuppression in each patient (tacrolimus, cyclosporin A, or sirolimus) and their average values and average dose of prednisone/day throughout the monitored period (Table 3 ). According to NODAT development during the monitored period, we assigned the patients to control group (n=103) or NODAT group (n=64). NODAT was diagnosed according to ADA (American Diabetes Association) criteria (Table 4) . We used a certified statistical program, MedCalc version 13.1.2,
Diagnostic criteria for diabetes mellitus
Symptoms of diabetes mellitus: polyuria, polydipsia, unexplained weight loss or Fasting blood glucose ³7 mmol/l or Glycemia in the 2nd hour of oGTT ³11.1 mmol/l 
Results
From the overall set of patients, 38.2% of patients (n=64) developed NODAT in the monitored period of 12 months after kidney transplantation. Patients in the NODAT group were statistically significantly older age at the time of kidney transplantation (P=0.004), they had significantly greater waist circumference 12 months after kidney transplantation (P<0.0001), and had significantly higher average level of sirolimus (P=0.0262) throughout the 12 monitored months after kidney transplantation. The average levels of triglycerides and cholesterol were without statistically significant differences in both groups (P=0.5358 for triglycerides, P=1.000 for cholesterol) (Table 5 ).
However, in more than 50% of patients (P=0.0572) with NODAT, combined lipid-lowering therapy was necessary for achieving optimal values of lipids ( Table 7) . By using correlation coefficient we proved that greater waist circumference was related to higher incidence of NODAT (r=0.1935, [95% CI: 0.01156 to 0.3630], P=0.0374). In the series of patients with NODAT we identified the month after kidney transplantation in which NODAT was diagnosed. We found that NODAT had been diagnosed in a significantly higher number of patients (70%) in the first 6 months after kidney transplantation (P<0.001). We examined NODAT treatment in the series of patients with NODAT. A comparable number of patients were treated with peroral antidiabetics and insulin (42.5%), the fewest patients required combined treatment by peroral antidiabetics and insulin (6.3%), and 8.7% of patients were treated with diet. The value of creatinine 12 months after kidney transplantation was comparable in both groups (P=0.9144) similarly eGFR according to CKD EPI (P=0.0635). Finally, we compared the 12-month graft survival (death censored) and 12-month patient survival. Graft survival 12 months after kidney transplantation was 96.4%; in the control group it was 97.1% and in the NODAT group it was 95.3%, but we did not prove a statistical difference (P=0.5381) (Figure 2 ). Patient survival 12 months after KT was 97.6%; in the control group it was 98.1% and in the NODAT group it was 96.9%, but we did not prove a statistical difference (P=0.6113) (Figure 3 ). In the 12-month monitoring we identified patients whose death was caused by CVS diseases. Death was caused by CVS stroke in 50% of cases in the control group and in the group of patients with NODAT it was 100% of cases (P=0.1441). 
Discussion
In agreement with our results, age at the time of KT has been reported to be an independent risk factor for NODAT in other studies. Cosio et al. found up to 2.2 times higher risk of NODAT development in recipients older than 45 years compared with younger recipients [13] . Similarly, USRDS data show a strong relationship between age of recipient and NODAT development. Recipients age 45-59 years had 1.9 times higher risk of NODAT than recipients age 18-33 years.
In recipients older than 60 years, the risk of NODAT development was double that of younger recipients [14] . As the basic criterion for metabolic syndrome, waist circumference ³94 cm in men and ³80 cm in women (according to IDF criteria for men) was evaluated as an independent risk factor for NODAT in our analysis. A stronger relationship between waist circumference and cardiovascular morbidity and mortality was shown by several analyses in comparison with BMI in non-transplanted population. [15] . Our analysis indicates that we may expect this phenomenon also in the transplanted population. By using univariate analysis, Kodgire et al. found statistically significantly greater waist circumference at the time of kidney transplantation in a series of 50 patients after kidney transplantation from a living donor in the group of patients who had developed NODAT in the 12-month monitored period after kidney transplantation [16] . We also confirmed correlation between waist circumference and NODAT incidence. Studies comparing the relationship between waist circumference and risk of NODAT development, or the risk of CVS morbidity or mortality in patients after kidney transplantation are not available. However, considering data from the population of non-transplanted patients, further analyses are necessary. We have not proved a statistically significant difference between the values of cholesterol and TAG in the series of patients with NODAT in comparison with the control group. The results may, however, be affected by hypolipidemic therapy. In the control group, 54.5% of patients were administered statin and 34.5% were administered combined therapy (statin + ezetimibe) and in the NODAT group it was up to 57.7% of patients who were treated with combined hypolipidemic therapy. In a retrospective analysis by Porrini et al., hyperlipidemia before transplantation was assessed as a risk factor for NODAT, but only in the group of recipients who were administered tacrolimus. Hyperlipidemia is closely linked to insulin resistance and, consequently, to NODAT development [6, 17] . The type of immunosuppression did not show as a risk factor for NODAT development in our observation, which we put into the context of a very small group of patients receiving cyclosporine or mTOR inhibitors. Graft and patient survival was numerically lower in the NODAT group in our analysis (without statistical significance), which is probably related to the short follow-up time. NODAT decreases longterm allograft survival. Most, if not all, of the adverse effect on allograft survival is due to the increased mortality associated with NODAT. For example, in a retrospective analysis of 27 707 transplant recipients, NODAT was associated with increased risk of allograft failure from any cause but not for death-censored graft loss (or graft loss without death) [18] . The mechanism by which NODAT may decrease allograft survival independent of increased mortality is not clear. Some have suggested that the recurrence of diabetic nephropathy may contribute to the increased rate of graft failure without death. Another possibility is that efforts to decrease diabetogenic immunosuppressive therapy to prevent NODAT and its complications may increase rates of rejection [14] . 
